BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Vivalis And Intervet/Schering-Plough Animal Health Sign A Commercial License


7/15/2009 11:12:13 AM

NANTES, FRANCE and BOOXMER, NETHERLANDS--(Marketwire - July 15, 2009) -

VIVALIS AND INTERVET/SCHERING-PLOUGH ANIMAL HEALTH SIGN A COMMERCIAL LICENSE TO USE THE EB66® CELL LINE FOR VIRAL VACCINE PRODUCTION AND EVALUATE THE PLATFORM FOR 12 NEW VACCINES.

VIVALIS (NYSE Euronext: VLS) and INTERVET/SCHERING-PLOUGH ANIMAL HEALTH today announced the signing of a commercial license, based on the letter of intent signed in 2008, to use the EB66® cell line, a VIVALIS proprietary technology, for the production of a veterinary vaccine. Moreover, through this agreement, INTERVET/SCHERING-PLOUGH ANIMAL HEALTH is also granted rights to test the EB66® cell line for the production of 12 different pathogens.

"VIVALIS is pleased to enter into this new agreement with INTERVET/SCHERING-PLOUGH ANIMAL HEALTH, a worldwide leader in animal health vaccines. This agreement highlights that the EB66® cell line became a new industry standard for the production of vaccines." said Franck Grimaud, VIVALIS CEO.

Terms of the agreement were not disclosed.

About the EB66® cell line.

EB66® cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth to high cell densities in suspension in a serum-free medium.

The BMF (Biologics Master File) for the registration of the EB66® cell line with the FDA (U.S. Food and Drug Administration) was filed June 27, 2008.

EB66® cell line is currently used or tested by 75% of the major players in vaccines. With 27 licenses already signed, the EB66® cell line is becoming a new standard cell substrate for biologics production.

*******************

Next financial press release:

22 July, after NYSE Euronext market closing: 2009 first-half sales

About Vivalis

VIVALIS (NYSE Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.

2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.

3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Merck, CSL Kaketsuken, Merial, Intervet Schering Plough, SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

Learn more about Vivalis at www.vivalis.com

+-------------------------+-+
|VIVALIS                  | |
+-------------------------+-+
|Listed on Euronext Paris | |
|- Compartment C of NYSE  | |
|Euronext                 | |
+-------------------------+-+
|Reuters: VLS.PA -        | |
|Bloomberg: VLS FP        | |
+-------------------------+-+
|Included in NYSE         | |
|Euronext's Next Biotech  | |
|index                    | |
+-------------------------+-+
+-------------------------+-+

About Intervet/Schering-Plough Animal Health

Intervet/Schering-Plough Animal Health is focusing on the research, development, manufacturing and marketing of animal health products. The company offers customers one of the broadest, most innovative animal health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species. For more information about Intervet/Schering-Plough Animal Health visit the following website: www.intervet.com

This information is provided by HUGIN


Investor Relations

VIVALIS

Franck Grimaud, CEO

Email: Email Contact NewCap

NEWCAP

Financial communication Agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email:vivalis@newcap.fr


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->